Medicinal liver damage in adults

drug-induced liver damage, drug-induced liver damage, drug hepatotoxicity, idiosyncrasy, Haya’s law

1. CSH guidelines for the diagnosis and treatment of drug-induced liver injury. Yue-cheng Yu, Yi-min Mao et al. Hepatol Int (2017) 11:221–241. DOI 10.1007/s12072–017–9793–2.

2. Galimova S. F. Medicinal lesions of the liver (part 1). Transplantology. 2011, No 1, pp. 13–21

3. Chalasani NP, Hayashi PH, Bonkovsky HL et al. ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol, 2014, 109(7): 950–966.

4. Bjornsson ES. Drug-induced liver injury: an overview over the most critical compounds. Arch Toxicol, 2015, 89(3): 327–334.

5. Sim S.C., Ingelman-Sundberg M. Update on allele nomenclature for humancytochromes P450 and the human cytochrome P450 allele (CYP-allele) nomenclature database // Methods Mol. Biol. – 2013. – № 987. – P. 251–259.

6. Ivashkin V. T. Diseases of the liver and biliary tract. Moscow. Publishing house “M-Vesti”, 2002, 416 p.

7. Bénichou C. Criteria of drug-induced liver disorders. Report of an international consensus meeting // J. Hepatol. – 1990. – Vol. 11, № 2. – P. 272–276.

8. Guengerich F. P. Common and uncommon cytochrome P450 reactions relatedto metabolism and chemical toxicity // Chem. Res. Toxicol. – 2001. – Vol. 14, № 6. – P. 611–650.

9. Ivashkin. V. T., Baranovsky A. Yu., Reichelson K. L. et al. Drug-induced liver damage (clinical recommendations for doctors). Moscow, 2019, 57 P.

10. Baykova I. E., Nikitin I. G. Drug-induced liver injuries. RMJ. 2009;1:4–10 (In Rus.).

11. Bueverov A. O. Drug-induced liver damage. RMZ. 2012, No 3, 107 p.

12. Licata A. Adverse drug reactions and organ damage: The liver. Eur J Intern Med, 2016, 28:9–16

13. Bjornsson E. S. Epidemiology and risk factors for idiosyncratic drug-induced liver injury. Semin Liver Dis, 2014, 34(2): 115–122.

14. Hillman L, Gottfried M, Whitsett M, et al. Clinical features and outcomes of complementary and alternative medicine induced acute liver failure and injury. Am J Gastroenterol. 2016;111(7):958–965.

15. Hoofnagle JH, Serrano J, Knoben JE, et al. LiverTox: a website on drug-induced liver injury. Hepatology. 2013;57(3):873–874.

16. Yimin M. HepaTox: The professional networking platform for promoting clinical and translational research of drug-induced liver injury in China. Chin Hepatol 2014;(8):575–576 (article in Chinese).

17. Reichelson K. L., Palgova L. K., Kondrashina E. A. et al. Medicinal lesions of the liver. Clinical recommendations for doctors. SPb. 2017, 116 p.

18. Naga P. Chalasani, Paul H. Hayashi et al. MDACG Clinical Guideline: Th e Diagnosis and Management of Idiosyncratic Drug-Induced Liver Injury. Am J Gastroenterol advance online publication, 17 June 2014; doi: 10.1038/ajg.2014.131.

19. Polunina T. E. Drug-induced liver injury. RMJ. Medical Review. 2018, no. 7(I), pp. 7–12.

20. Методические рекомендации по применению Vision International people group для оптимизации рациона питания и поддержания здоровья человека. М.,–2010.–296с. Guidelines for the use of Vision International people group to optimize the diet and maintain human health. Moscow, 2010, 296p.

21. Aithal G. P., Watkins P. B., Andrade R. J. et al. Case definition and phenotype standardization in drug-induced liver injury. Review // Clin.Pharmacol. Th er. 2011. Vol.89. № 6. P. 806–815.

22. Drug-induced liver injury / by ed. J.R odes, J. – P. Benhamou, A. T. Blei et al. Textbook of hepatology: from basic science to clinical practice. 3rd ed. Blackwell Publishing. 2007. P. 1211–1277. Clinical recommendations for the correction of hepatotoxicity induced by antitumor chemotherapy. Moscow, 2014.

23. Клинические рекомендации по коррекции гепатотоксичности индуцированной противоопухолевой химиотерапией. М., 2014.

24. Matveev A. V. Hepatoprotectors. Analysis of international studies on drugs of the group of drugs for the liver. Simferopol. IT “ARIAL”. 2013, 382 P.

25. Tsai JH, Liu JY, Wu TT, Ho PC, Huang CY, Shyu JC, et al. Efects of silymarin on the resolution of liver ibrosis induced by carbon tetrachloride in rats. J. Viral Hepat. 2008 Jul;15(7):508–14.

26. Santini D. S-adenosylmethionine (AdoMet) supplementation for treatment of chemotherapy-induced liver injury / D. Santini, B. Vincenzi, C. Massacesi [et al.] // Anticancer Res. – 2003. – Vol. 23, № 6D. – P. 5173–5179.

27. Lazebnik L. B., Golovanova E. V., Alekseenko S. A., Bueverov A. O. et al. Russian Consensus “Hyperammonemia in Adults”. Experimental and Clinical Gastroenterology. 2019;172(12): 4–23. (In Russ.) DOI: 10.31146/1682-8658-ecg-172-12-4-23

28. Beuers U, Boberg KM., Chapman RW et al. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol, 2009, 51(2): 237–267.

29. Nathwani RA, Kaplowitz N. Drug hepatotoxicity. Clin Liver Dis, 2006, 10: 207–217

30. Lazebnik L. B., Zvenigorod L. A., Morozov I. A., She pele va S. D. Clinical and morphological changes in the liver with atherogenic dyslipidemia and with statins. Therapeutic Archive. 2003; 8: 51–55.

31. Zvenigorodskaya L. A., Lazebnik L. B., Cherkashova E. A., Efremov L. I. Statin hepatitis. Diffi cult patient. 2009, No. 4–5, pp. 44–49.

32. Liu X, Li X. An Observation of Essentiale’s Efects on the Liver Protection during the Medical Treatment of Tuberculosis. Journal of Clinical Pulmonary Medicine. 2002;7(1):18–9

33. Gurevich V, Bondarenko B, Gundermann KJ. Polyunsaturated phospholipids increase the hypolipidemic efect of lovastatin. Eur J Int Med. 1997;(8):13–8.

34. Goretskaya M. V., Sheybak V. M. Hepatoprotective properties of taurine with paracetamol intoxication. News of the National Academy of Sciences of Belarus. 2013, No. 3, pp. 96–101.

35. Koroleva M. V. Possibilities of pathogenetic therapy of drug damage to the liver with tuberculosis. Journal of Infectology, 2014, Volume 6, No. 3.

36. Shikh E. V., Sizova O. S., Makhova A. A. Possibilities of using hepatoprotectors in combination therapy of onychomycosis. RMZ. 2014;(6):1–6.

37. Paltsev A. I., Yeremenko A. A., Torgashov M. N. He pa toprotective role of placenta hydrolisat – laennec in the treatment of patients with viral and parasitic liver diseases. Experimental and Clinical Gastroenterology. 2016;(11):94–99. (In Russ.)

38. Minushkin O. N., Maksimov V. A., Paltsev A. I., Saifutdinov R. G., Chernyshev A. L., Gromova R. A., Gusakova E. V., Radchenko V. G., Lazebnik L. B. Recommendations for the use of human placenta hydrolysate in liver diseases. Experimental and Clinical Gastroenterology. 2016;(12):75–77. (In Russ.)

39. Minushkin O. N., Maslovsky L. V., Zverkov I. V. et al. “Laennec” in the treatment of certain liver diseases. Effective pharmacotherapy. 2008, No. 1, pp. 30–34.

40. Gromova O. A., Torshin I. Yu., Minushkin O. N. et al. On the effectiveness and molecular mechanisms of action of the drug “Laennec” in the treatment of pathological liver conditions associated with iron deposition in the liver. The Medical Journal of Life. 2015, No. 1 (1), pp. 44–51.

41. Eremina E. Yu. Pathology of the digestive system in pregnant women. Lambert Academic Publishing. Germany. 2011.

42. Tkacheva O. N., Bevz A. Yu., Ushkalova E. A., Chu kha reva N. A. The first all-Russian pharmacoepidemiological study “Epidemiology of the use of drugs in pregnant women”: the main results. Obstetrics and gynecology. 2011, No. 4, pp. 112–117.

43. Drug Interaction Studies-Study Design, Data Analysis, and Implications for Dosing and Labeling.URL: http://www.fda.gov/cder/guidance/6695 dft.htm.

44. Marschall H. U., Wagner M., Zollner G., Trauner M. Clinical hepatotoxicity. Regulation and treatment with inducers of transport and cofactors. Molecular pharmaceutics. 2007. V. 4. P. 895–910.

45. Bjornsson E., Jerlstad P., Bergqvist A., Olsson R. Fulminant drug–induced hepatic failure leading to death or liver transplantation in Sweden. Scandinavian journal of gastroenterology. 2005. V. 40. P. 1095–1101.

46. Eremina E. Yu., Gerasimenko A. V., Gerasimenko I. V. Drug-induced liver damage in pregnant women. Medical almanac. 2013, No. 1 (25), pp. 55–59.